Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study designed to assess the effect of hepatic insufficiency on the PK of
pacritinib by study of 14-day BID dosing of pacritinib in subjects with moderate and severe
hepatic impairment compared to healthy matched control subjects with normal liver function.
Safety and tolerability of multiple day dosing of pacritinib in the subject populations will
also be evaluated.